Mexico: Applying the experimental use exception in patent infringements

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Mexico: Applying the experimental use exception in patent infringements

Sponsored by

olivares-400px.jpg
greyson-joralemon-9ibqihqhuhc-unsplash.jpg

Armando Arenas of Olivares explores how Mexico has interpreted the experimental and academic use exception

For many years, the experimental and academic use exception was incorrectly applied in Mexico to declare third parties who imported raw materials while the patents that protected the correlative active principle were still in force, as infringers. This is because the companies alleged that, according to their import requests, these authorisations had been granted by the sanitary authorities for experimentation purposes without commercial aims.

Therefore, to avoid patent infringement, it was sufficient for the defendant to exhibit the import authorisation granted by the sanitary authority (Federal Commission for the Protection against Sanitary Risks COFEPRIS). The import authorisation also had to include a legend stating that the importation had been authorised for experimentation purposes.

Additionally, some infringing companies enforced the Roche-Bolar exception and the experimental use exception at the same time, generating confusion in the Mexican Institute of Industrial Property (IMPI). The institute chose to declare the raw material importing companies (trading companies) as infringers, considering that their activity was only for commercial purposes and denied the infringement if the defendants proved that they were pharmaceutical companies applying the benefit of the Roche-Bolar exception.

Recently, in cases handled by Olivares, two different circuit courts have clarified the correct interpretation of the experimental and academic use exception. The rulings  stated, in accordance with the most basic rules of the burden of proof, that it was not enough to exhibit an import permit that indicates that the destination of the raw material to consider that such exception is applicable. It stated that it was however necessary to demonstrate with another type of evidence, as they constitute their own facts and it was the defendants who asserted the said exception, which is the type of activity that was specifically carried out for purely experimental purposes. These new criteria have now caused the IMPI to correctly apply this exception for the benefit of the patent protection system and its holders.

 
Armando ArenasPartner, OlivaresE: armando.arenas@olivares.mx  

more from across site and SHARED ros bottom lb

More from across our site

Monika Żuraw, founder of Żuraw & Partners, discusses why IP should be part of the foundation of a business, and taking on projects that others walk away from
Lawyers say attention will turn to the UK government’s AI consultation after judgment fails to match pre-trial hype
Susan Keston and Rachel Fetches at HGF explain why the CoA’s decision to grant the UPC’s first permanent injunction demonstrates the court’s readiness to diverge from national court judgments
IP, M&A, life sciences and competition partners advised on deal that brings together brands such as ‘Huggies’ and ‘Kleenex’ with ‘Band-Aid’ and ‘Tylenol’
Stability AI, represented by Bird & Bird, is not liable for secondary copyright infringement, though Fieldfisher client Getty succeeds in some trademark claims
Plasseraud IP says it is eyeing AI and quantum computing expertise with new hire from Cabinet Netter
In the fifth episode of a podcast series celebrating the tenth anniversary of IP Inclusive, we discuss the ‘Careers in Ideas’ network and how to open access to the profession
McGuireWoods’ focussed experimentation and disciplined execution of AI tools is sharpening its IP practice
As Marshall Gerstein celebrates its 70-year anniversary, Jeffrey Sharp, managing partner, reflects on lessons that shaped both his career and the firm’s success
News of two pharma deals involving Novo Nordisk and GSK and a loss for Open AI were also among the top talking points
Gift this article